Can Krazati treat KRAS G12C mutations?

Can Krazati (adagrasib) treat KRAS G12C mutations?

Yes. Krazati is designed to treat cancers with the KRAS G12C mutation, since adagrasib targets the KRAS G12C protein variant.

What cancers is Krazati used for with KRAS G12C?

Krazati is used in KRAS G12C–mutated cancers (the exact indication depends on the patient population and prior treatments, per regulatory labeling).

How does KRAS G12C treatment differ from other KRAS mutations?

Krazati is specifically for KRAS G12C. It is not indicated for other KRAS mutation types (such as KRAS G12D or KRAS G12V), because those variants require different targeting approaches.

Where can I check Krazati’s current KRAS G12C indication and drug details?

For the latest searchable information on adagrasib/Krazati and KRAS G12C-related coverage, you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/